
Sign up to save your podcasts
Or


Amid declining rates of vaccinations in the U.S, virus mutations and a crisis in India, is herd immunity from COVID-19 still achievable? The latest insights from Biotech equity analyst, Matthew Harrison.
By Morgan Stanley4.8
12461,246 ratings
Amid declining rates of vaccinations in the U.S, virus mutations and a crisis in India, is herd immunity from COVID-19 still achievable? The latest insights from Biotech equity analyst, Matthew Harrison.

1,715 Listeners

977 Listeners

406 Listeners

1,173 Listeners

2,175 Listeners

198 Listeners

686 Listeners

1,044 Listeners

191 Listeners

70 Listeners

80 Listeners

1,574 Listeners

436 Listeners

212 Listeners

118 Listeners

81 Listeners

0 Listeners